Som P. Singh1*
Anand Chockalingam2
- 1Department of Internal Medicine, University of Texas Health Sciences Center at Houston, Houston, TX, United States
- 2Department of Cardiology, Charleston Area Medical Center, Charleston, WV, United States
Introduction
Ghrelin has built a profile as a peptide hormone critical in appetite and adiposity metabolic pathways, and it is associated as a ligand for growth hormone secretagogue receptors (1). It is largely produced in the stomach and small intestine, then secreted into the bloodstream. However, there are also reports of ghrelin production outside the gastrointestinal system, including in vital organs such as the kidney and the lung (2, 3). The active structure of ghrelin has largely been identified as a 28-amino-acid peptide. There is an n-octanoyl group attached to serine at position 3 that has been demonstrated to play a key role in its ability to bind to the growth hormone secretagogue receptors and function in numerous physiological processes, including growth hormone release and appetite (4).
Additionally, a growing body of literature has observed its role in cardiovascular pathophysiology (5, 6). Ghrelin has been demonstrated to be expressed by human cardiomyocytes on culture medium (7). Moreover, growth hormone secretagogue receptors have also been found to be localized in cardiac tissue, including in the myocardial and smooth muscle cells (8, 9). Among the effects of ghrelin in cardiovascular diseases, experimental studies have demonstrated a reduction in the incidence of ventricular tachyarrhythmia in a mouse myocardial infarction model (10). Moreover, experimental evidence also suggests that des-acyl ghrelin had beneficial cardiovascular effects in the settings of doxorubicin-induced cardiomyopathy via limiting cardiac fibrosis and cellular apoptosis (11).
There is also a growing body of literature is investigating ghrelin as a key target in heart failure (6). As interest in this peptide hormone rises leading to new pre-clinical and clinical data to emerge, there is a need to examine key areas and highlight future areas for further investigation. This paper highlights three key areas of ghrelin in heart failure and discusses what should be further investigated (Figure 1).
Figure 1. Areas of investigation regarding ghrelin in heart failure.
Ghrelin as an inotrope
The use of inotropic agents in patients with heart failure has been seen in the inpatient setting, such as those with low cardiac output, hypotension, and end-organ dysfunction (12). They have also been used as hemodynamic optimization therapy to bridge to heart transplantation or prior left ventricle assist device (LVAD) implantation and in palliative settings (12–14). A key physiological effect of ghrelin is its ability to modulate cardiac contractility, functioning as a positive inotrope. However, the exact mechanisms of how this is performed by ghrelin continue to be investigated in pre-clinical and clinical studies. One of the earliest randomized trials where human synthetic ghrelin infusion was provided to individuals with clinical congestive heart failure (CHF) was by Nagaya et al. in 2001 (15). This study found that the group of individuals with CHF receiving ghrelin infusion had a statistically significant increase in stroke volume and cardiac index. Many years later, a randomized trial by Lund et al. in 2023 with 31 patients with heart failure with reduced ejection fraction, where individuals with human synthetic ghrelin infusion were provided to patients, and this group had a statistically significant 28% increase in cardiac output and 14.5% increase in stroke volume (16). Lund et al. also demonstrated an experimental ex vivo study were isolated mouse cardiomyocytes, with the administration of acyl ghrelin, increased load-dependent contractility. However, this occurred independent of preload or afterload, and most importantly, without affecting cellular calcium mobilization (16). This mechanism may decrease the risk of complications such as tachycardia, arrythmia, hypotension and cardiac ischemia that limit use of established inotropic agents (17, 18).
Additionally, ghrelin has been demonstrated to have protective effects in cardiovascular remodeling, which provides an advantageous profile as an inotrope. However, these cardioprotective effects are still not well understood. Eid et al. reported an animal model that suggested that the activation of JAK2/STAT3 signaling and inhibition of STAT1 signaling inhibited cardiac myocyte apoptosis during cardiovascular remodeling (19). Mao et al. also reported that these effects contribute to a cholinergic anti-inflammatory process in cardiac hypertrophy (20). Ghrelin has also demonstrated decreased sympathetic activity as well as anti-arrhythmic effects in subjects following myocardial infarction (10, 21).
Currently available inotropic agents for clinical practice are used for acute hemodynamic benefits despite increasing mortality (22). As the evolving literature on metabolics suggests, ghrelin infusion may not increase cardiac mortality in acute heart failure, this could be a key area of future investigation. When present, right heart failure significantly worsens clinical outcomes. Emerging data among individuals with heart failure with reduced ejection fraction (HFrEF), treatment with acyl ghrelin group improves right ventricular-pulmonary arterial coupling compared to placebo (23). This is key as increases in cardiac output could physiologically disrupt right ventricular-pulmonary arterial coupling in the setting of HFrEF and impair right ventricular function more (24). These findings are promising, and future investigations could evaluate ghrelin for managing acute heart failure instead of currently established cardiac inotropic therapies.
Ghrelin as a heart failure biomarker
Biomarkers can aid in providing risk and severity data and guide therapeutic management for patients with heart failure (25). In addition to positive inotropy, ghrelin may also serve as a biomarker for individuals with heart failure and has even been explored as a potential biomarker in diabetic cardiomyopathy (26, 27). Yuan et al. reported a cohort of 241 individuals with advanced heart failure, and this study found a statistically significant positive correlation between ghrelin concentration and NT-proBNP levels and heart failure severity (28). However, there needs to be further investigation to better understand the behavior profile of ghrelin in heart failure, as the findings by Chen et al. demonstrated that plasma ghrelin levels were significantly lower in their cohort of patients with CHF compared to controls and correlated inversely with plasma NT-proBNP levels (29). Moreover, the utility of ghrelin as a biomarker must be explored by future investigations to determine if it guides therapeutic decisions in heart failure. Ghrelin levels may be affected by heart failure stage, comorbidities, and by sampling postprandial, as in some of the above studies. Overall, ghrelin may serve as a new biomarker that aids clinicians in creating a more personalized management plan for their patients (30).
Ghrelin and cardiac cachexia
The presence of cardiac cachexia is linked to considerable morbidity in heart failure (31, 32). Nagaya et al. reported that participants with CHF and cardiac cachexia demonstrated high plasma ghrelin levels (33). Moreover, there is literature that suggests that there may be resistance to appetite stimulation by ghrelin in heart failure, and this may be a compensatory response in cardiac cachexia (34, 35). The presence of cardiac cachexia may be a key selection factor for which patients may optimally benefit from exogenous ghrelin administration as well as advanced heart failure therapies (36). This makes it imperative for further trials to be designed that observe the effects of exogenous ghrelin administration on cardiac contractility and output for patients with CHF associated with cardiac cachexia and those without cardiac cachexia. Likewise, this makes it critical in developing studies that observe the role of ghrelin as a biomarker for patients in guiding treatment plans.
Conclusion
Pre-clinical and clinical studies demonstrate key promise for ghrelin as a heart failure biomarker and an inotropic agent, given its prior demonstration of increased cardiac contractility and inhibition of cardiac myocyte apoptosis during cardiovascular remodeling. This raises attention to the need to investigate further which patients are most appropriate for this inotropic administration in larger cohorts. This is critical considering the numerous organ systems upon which ghrelin and growth hormone secretagogue receptors are involved in. Additionally, there is a paucity of data observing the long-term cardiovascular effects of ghrelin administration and cardiac cachexia. However, this paper is not without its limitations as well. This paper aims to highlight critical data on ghrelin in heart failure metabolics but does not encompass the complete potential of this hormonal peptide in heart failure.
Author contributions
SS: Conceptualization, Project administration, Visualization, Writing – original draft, Writing – review & editing. AC: Conceptualization, Supervision, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. (2015) 4(6):437–60. doi: 10.1016/j.molmet.2015.03.005
2. Koutouratsas T, Kalli T, Karamanolis G, Gazouli M. Contribution of ghrelin to functional gastrointestinal disorders’ pathogenesis. World J Gastroenterol. (2019) 25(5):539–51. doi: 10.3748/wjg.v25.i5.539
3. Young ER, Jialal I. Biochemistry, Ghrelin. 2023 Jul 17. In: StatPearls. Treasure Island (FL): StatPearls Publishing (2025).
4. Delporte C. Structure and physiological actions of ghrelin. Scientifica (Cairo). (2013) 2013:518909. doi: 10.1155/2013/518909
5. Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol. (2012) 59(1):8–13. doi: 10.1016/j.jjcc.2011.11.002
6. Theodorakis N, Feretzakis G, Kreouzi M, Anagnostou D, Hitas C, Verykios VS, et al. Ghrelin: an emerging therapy for heart failure. Clin Endocrinol (Oxf). (2025) 102(4):403–12. doi: 10.1111/cen.15196
7. Iglesias MJ, Piñeiro R, Blanco M, Gallego R, Diéguez C, Gualillo O, et al. Growth hormone releasing peptide (Ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. (2004) 62(3):481–8. doi: 10.1016/j.cardiores.2004.01.024
8. Sullivan R, Randhawa VK, Lalonde T, Yu T, Kiaii B, Luyt L, et al. Regional differences in the Ghrelin-growth hormone secretagogue receptor signalling system in human heart disease. CJC Open. (2020) 3(2):182–94. doi: 10.1016/j.cjco.2020.10.015
9. Papotti M, Ghè C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. (2000) 85(10):3803–7. doi: 10.1210/jcem.85.10.6846
10. Mao Y, Tokudome T, Otani K, Kishimoto I, Nakanishi M, Hosoda H, et al. Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology. (2012) 153(7):3426–34. doi: 10.1210/en.2012-1065
11. Pei XM, Yung BY, Yip SP, Ying M, Benzie IF, Siu PM. Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway. Am J Physiol Endocrinol Metab. (2014) 306(3):E311–23. doi: 10.1152/ajpendo.00123.2013
12. Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. (2015) 16(12):29060–8. doi: 10.3390/ijms161226147
13. Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the heart failure association of the European Society of Cardiology. Eur J Heart Fail. (2023) 25(4):457–68. doi: 10.1002/ejhf.2814
14. Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation. (2010) 121(14):1655–60. doi: 10.1161/CIRCULATIONAHA.109.899294
15. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. (2001) 86(12):5854–9. doi: 10.1210/jcem.86.12.8115
16. Lund LH, Hage C, Pironti G, Thorvaldsen T, Ljung-Faxén U, Zabarovskaja S, et al. Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization. Eur Heart J. (2023) 44(22):2009–25. doi: 10.1093/eurheartj/ehad100
17. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. (1995) 38(2):167–80. doi: 10.1016/S0033-0620(05)80005-2
18. Lee JA, Allen DG. Calcium sensitisers: mechanisms of action and potential usefulness as inotropes. Cardiovasc Res. (1997) 36(1):10–20. doi: 10.1016/s0008-6363(97)00174-0
19. Eid RA, Alkhateeb MA, Eleawa S, Al-Hashem FH, Al-Shraim M, El-Kott AF, et al. Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling. Basic Res Cardiol. (2018) 113(2):13. doi: 10.1007/s00395-018-0671-4
20. Mao Y, Tokudome T, Kishimoto I, Otani K, Nishimura H, Yamaguchi O, et al. Endogenous ghrelin attenuates pressure overload-induced cardiac hypertrophy via a cholinergic anti-inflammatory pathway. Hypertens Dallas Tex 1979. (2015) 65(6):1238–44. doi: 10.1161/HYPERTENSIONAHA.114.04864
21. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, et al. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol-Heart Circ Physio. American Physiological SocietyL. (2008) 294(1):H426–32. doi: 10.1152/ajpheart.00643.2007
22. Gao F, Zhang Y. Inotrope use and intensive care unit mortality in patients with cardiogenic shock: an analysis of a large electronic intensive care unit database. Front Cardiovasc Med. (2021) 8:696138. doi: 10.3389/fcvm.2021.696138
23. Erhardsson M, Faxén UL, Venkateshvaran A, Hage C, Pironti G, Thorvaldsen T, et al. Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure. ESC Heart Fail. (2024) 11(1):601–5. doi: 10.1002/ehf2.14580
24. Wang J, Li X, Jiang J, Luo Z, Tan X, Ren R, et al. Right ventricular-pulmonary arterial coupling and outcome in heart failure with preserved ejection fraction. Clin Cardiol. (2024) 47(7):e24308. doi: 10.1002/clc.24308
25. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. American Heart Association. (2017) 135(22):e1054–91. doi: 10.1161/CIR.0000000000000490
26. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. (2004) 110(24):3674–9. doi: 10.1161/01.CIR.0000149746.62908.BB
27. Sullivan R, McGirr R, Hu S, Tan A, Wu D, Charron C, et al. Changes in the cardiac GHSR1a-Ghrelin system correlate with myocardial dysfunction in diabetic cardiomyopathy in mice. J Endocr Soc. (2017) 2(2):178–89. doi: 10.1210/js.2017-00433
28. Yuan Y, Huang F, Deng C, Zhu P. The additional prognostic value of Ghrelin for mortality and readmission in elderly patients with acute heart failure. Clin Interv Aging. (2020) 15:1353–63. doi: 10.2147/CIA.S259889
29. Chen Y, Ji XW, Zhang AY, Lv JC, Zhang JG, Zhao CH. Prognostic value of plasma ghrelin in predicting the outcome of patients with chronic heart failure. Arch Med Res. (2014) 45(3):263–9. doi: 10.1016/j.arcmed.2014.01.004
30. Berezin AE, Berezin AA. Biomarkers in heart failure: from research to clinical practice. Ann Lab Med. (2023) 43(3):225–36. doi: 10.3343/alm.2023.43.3.225
31. Soto ME, Pérez-Torres I, Rubio-Ruiz ME, Manzano-Pech L, Guarner-Lans V. Interconnection between cardiac cachexia and heart failure-protective role of cardiac obesity. Cells. (2022) 11(6):1039. doi: 10.3390/cells11061039
32. Valentova M, Anker SD, von Haehling S. Cardiac cachexia revisited: the role of wasting in heart failure. Heart Fail Clin. (2020) 16(1):61–9. doi: 10.1016/j.hfc.2019.08.006
33. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. (2001) 104(17):2034–8. doi: 10.1161/hc4201.097836
34. Lund LH, Williams JJ, Freda P, LaManca JJ, LeJemtel TH, Mancini DM. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur J Heart Fail. (2009) 11(8):789–94. doi: 10.1093/eurjhf/hfp088
35. Attanasio P, Anker SD, Doehner W, von Haehling S. Hormonal consequences and prognosis of chronic heart failure. Curr Opin Endocrinol Diabetes Obes. (2011) 18(3):224–30. doi: 10.1097/MED.0b013e3283469505
Keywords: Ghrelin, heart failure, biomarker, inotrope, cachexia
Citation: Singh SP and Chockalingam A (2025) Ghrelin peptide in heart failure: when is showtime?. Front. Cardiovasc. Med. 12:1574521. doi: 10.3389/fcvm.2025.1574521
Received: 11 February 2025; Accepted: 20 May 2025;
Published: 4 July 2025.
Edited by:
Massimo Iacoviello, University of Foggia, ItalyReviewed by:
Sandra Feijóo-Bandín, Carlos III Health Institute (ISCIII), SpainCopyright: © 2025 Singh and Chockalingam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Som P. Singh, c29tLnAuc2luZ2hAdXRoLnRtYy5lZHU=